KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
94 hedge funds and large institutions have $357M invested in KalVista Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 12 closing their positions.
50% more capital invested
Capital invested by funds: $237M → $357M (+$120M)
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
5.38% more ownership
Funds ownership: 98.85% → 104.23% (+5.4%)
3% more funds holding
Funds holding: 91 → 94 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$12M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$7.4M |
| 3 |
Millennium Management
New York
|
+$5.28M |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$4.37M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$4.67M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$4.06M |
| 3 |
SCM
Suvretta Capital Management
New York
|
-$3.09M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$1.72M |
| 5 |
Renaissance Technologies
New York
|
-$1.47M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Osaic Holdings
Scottsdale,
Arizona
| – | -$1K | -100 | Closed |
|
|
QCG
102
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$112 | -8 | -23% |
|
|
C
103
Covestor
London,
United Kingdom
| – | +$210 | +15 | New |
|
|
PA
104
Parallel Advisors
San Francisco,
California
| – | +$266 | +19 | New |
|
KALV Hedge Fund Activity: Q3 2022 in Review
94 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2022, worth a combined $357M — up 50% from $237M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new KALV positions and 12 closed out — a net gain of 3 holders — while 29 added to existing stakes and 31 trimmed.
The largest buyer was OrbiMed, adding an estimated $12M. The largest seller was Woodline Partners, cutting an estimated $4.67M.
- 94 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2022, up from 91 in Q2 2022.
- Funds reported $357M of KalVista Pharmaceuticals stock for Q3 2022, up 50% quarter-over-quarter.
- 15 funds opened new KalVista Pharmaceuticals positions in Q3 2022 and 12 closed out, a net change of +3 holders.
- The largest KalVista Pharmaceuticals buyer in Q3 2022 was OrbiMed, an estimated $12M added.
- The largest KalVista Pharmaceuticals seller in Q3 2022 was Woodline Partners, an estimated $4.67M sold.
Based on aggregated 13F filings for Q3 2022.